Lonza and Clovis Open New Monoplant for Ovarian Cancer Drug

Lonza has world-leading HPAPI development and manufacturing capabilities at its...
Lonza has world-leading HPAPI development and manufacturing capabilities at its Visp (CH) site with large commercial scale capacity.

Lonza and Clovis Oncology have opened a new, dedicated production train for Rubraca (rucaparib), at Lonza’s Visp site in Switzerland. Rubraca is Clovis’ US- and EU-approved drug for several ovarian cancer indications. Clovis Oncology CEO and President Patrick Mahaffy and Lonza Pharma & Biotech COO Marc Funk toured the new facility and spoke to staff and guests and highlighted the potential of this new therapy for patients.

Under a long-term agreement, the new, state-of-the-art monoplant enables security of supply and flexibility to rapidly meet changes in market demand for rucaparib. During construction of the Clovis monoplant, Lonza manufactured rucaparib in its existing production trains at Visp, providing Clovis dedicated and uninterrupted access to capacity. This tailored supply strategy supports Lonza active pharmaceutical ingredient (API) customers’ specific needs during development, commercialization and ongoing market supply.

Lonza constructed the new production train for rucaparib, an oral, small molecule inhibitor of PARP1, PARP2 and PARP3, using 20 years’ experience in commercial-scale, high-containment manufacturing. The new facility offers leading-edge technologies including extensive automation and on-line analytical monitoring designed to enable real-time release testing. This approach facilitates process monitoring and consistency and gives Clovis Oncology faster and agile delivery, with optimized cost of goods.

“This partnership is a great example of how we can support commercial stage biotech companies through innovation in manufacturing technology and flexible business models,” said Marc Funk, COO Lonza Pharma & Biotech. “Lonza continues to invest in infrastructure for the safe and efficient production of highly potent active pharmaceutical ingredients (HPAPIs).”

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.